Rexahn Pharmaceuticals announces US patent for cognition enhancement

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,842,683 entitled, "Neurotherapeutic Compositions and Methods."

“This new patent coverage for cognition enhancement using beta-lactam compounds further broadens our CNS-related portfolio and strengthens our intellectual property position with potential treatments for neurodegeneration.”

The patent covers a method of enhancing cognitive function and treating cognitive disorders such as dementia, amnesia or Altzheimer's disease, using beta-lactam compounds. The patent also covers the combination with one or more other enzyme inhibitors, for example effective amounts of a beta-lactamase inhibitor, or another NAALADase inhibitor, or a P-glycoprotein efflux inhibitor, to enhance brain levels of the active compound.

Rick Soni, President of Rexahn, noted, "This new patent coverage for cognition enhancement using beta-lactam compounds further broadens our CNS-related portfolio and strengthens our intellectual property position with potential treatments for neurodegeneration."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights long-term risks of prostate cancer treatment